122 related articles for article (PubMed ID: 10999732)
1. Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
[TBL] [Abstract][Full Text] [Related]
2. The erythromycin breath test for the prediction of drug clearance.
Rivory LP; Slaviero KA; Hoskins JM; Clarke SJ
Clin Pharmacokinet; 2001; 40(3):151-8. PubMed ID: 11327195
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
4. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
5. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.
Gharaibeh MN; Gillen LP; Osborne B; Schwartz JI; Waldman SA
J Clin Pharmacol; 1998 Jun; 38(6):492-5. PubMed ID: 9650537
[TBL] [Abstract][Full Text] [Related]
6. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
7. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
Krivoruk Y; Kinirons MT; Wood AJ; Wood M
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):608-14. PubMed ID: 7995002
[TBL] [Abstract][Full Text] [Related]
10. In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4.
Nicandro JP; Tsourounis C; Frassetto L; Guglielmo BJ
J Herb Pharmacother; 2007; 7(1):39-56. PubMed ID: 17594986
[TBL] [Abstract][Full Text] [Related]
11. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
[TBL] [Abstract][Full Text] [Related]
12. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.
McCrea J; Prueksaritanont T; Gertz BJ; Carides A; Gillen L; Antonello S; Brucker MJ; Miller-Stein C; Osborne B; Waldman S
J Clin Pharmacol; 1999 Dec; 39(12):1212-20. PubMed ID: 10586386
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4 and the erythromycin breath test.
Wagner D
Clin Pharmacol Ther; 1998 Jul; 64(1):129-30. PubMed ID: 9695728
[No Abstract] [Full Text] [Related]
14. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test.
Tateishi T; Graham SG; Krivoruk Y; Wood AJ
Br J Clin Pharmacol; 1995 Oct; 40(4):411-2. PubMed ID: 8554946
[No Abstract] [Full Text] [Related]
15. Erythromycin breath test and clinical transplantation.
Watkins PB
Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
[TBL] [Abstract][Full Text] [Related]
16. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
Lown KS; Kolars JC; Thummel KE; Barnett JL; Kunze KL; Wrighton SA; Watkins PB
Drug Metab Dispos; 1994; 22(6):947-55. PubMed ID: 7895614
[TBL] [Abstract][Full Text] [Related]
17. Effects of uptake and efflux transporter inhibition on erythromycin breath test results.
Frassetto LA; Poon S; Tsourounis C; Valera C; Benet LZ
Clin Pharmacol Ther; 2007 Jun; 81(6):828-32. PubMed ID: 17361125
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
Prueksaritanont T; Vega JM; Rogers JD; Gagliano K; Greenberg HE; Gillen L; Brucker MJ; McLoughlin D; Wong PH; Waldman SA
J Clin Pharmacol; 2000 Nov; 40(11):1274-9. PubMed ID: 11075313
[TBL] [Abstract][Full Text] [Related]
19. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics.
Harris RZ; Tsunoda SM; Mroczkowski P; Wong H; Benet LZ
Clin Pharmacol Ther; 1996 Apr; 59(4):429-35. PubMed ID: 8612388
[TBL] [Abstract][Full Text] [Related]
20. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
